129 results about "Toxoplasmosis" patented technology

Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii (T. gondii) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and / or imidazo[1,5-a]pyrazine inhibitors, of the formula,wherein the variables X, Y, Z, L, R1, and R3 are defined herein.

The invention relates to a primer pairs for rapid detection of toxoplasmosis nucleic acid, a kit and a detection method. The primer pairs for rapid detection of toxoplasmosis nucleic acid comprises aforward primer, a reverse primer and a probe for detecting genome B1 gene sequence of toxoplasmosis. The kit comprises the following contents: a lysate, a diluent, a lyophozyme tube containing the primers, a positive quality control and a negative quality control. The detection includes the process of carrying out a normal-temperature nucleic acid amplification technology by using the kit. Throughmultiple enzymatic reactions of DNA helicase, single-stranded DNA binding protein, DNA polymerase and the like, target DNA can be amplified by millions of times under the condition of constant temperature 37-45 DEG C within 10-30 min; and with the cooperation of the fluorescence detection technique, rapid detection of DNA to be tested can be realized. The detection method of the invention has advantages of simple operation, short time and low requirement on equipment, and is very suitable for rapid diagnosis of pet infectious diseases.

The invention relates to a soluble powder for treating livestock and poultry bacterial infection and parasitosis, comprising nortloxacin lactate, trimethoprim and auxiliary materials, the medicament of the invention is taken as antibiotic medicament, is mainly used for treating various diseases and parasitosis caused by sensitive bacterias, has better curative effects for pig toxoplasmosis, pig hydropsy, poultry, rabbit coccidiosis, the nortloxacin lactate and the trimethoprim are compatible with each other for using and generating cooperating action, the medicament of the invention has excellent oral administration absorption effect and high safety.

The invention provides polypeptide fragments derived from TgAMA-1, nucleic acids that encode the polypeptide fragments, and TgAMA-binding polypeptides such as antibodies. Methods for using the polypeptide and nucleic acid molecules to produce vaccines are also provided. In addition the invention provides methods involving use of the polypeptides, nucleic acids, and binding polypeptides, such as antibodies, for the prevention and treatment of Toxoplasmosis.

The present invention provides attenuated Toxoplasma gondii knockout mutants of the de novo pyrimidine synthesis pathway and use of the same in vaccines and methods of providing an immune response and protecting a subject against infection by T. gondii and a non-T. gondii disease.

The invention relates to a formula of a medicament for treating swine high fever and a using method thereof. The medicament is prepared by dissolving 0.5 to 25 percent of Chinese angelica extract, 0.5 to 25 percent of rhubarb extract, 0.5 to 25 percent of Himalayan teasel root extract, 0.5 to 25 percent of common clubmoss herb extract, 0.5 to 25 percent of liquorice root extract, 0.5 to 25 percent of croton seed extract, 0.5 to 25 percent of toad venom, 0.5 to 25 percent of cicada slough extract, 0.5 to 25 percent of radix scutellariae extract, 0.5 to 25 percent of honeysuckle extract and 0.5 to 25 percent of common andrographis herb extract with solvent normal saline to obtain an injection, wherein the sum of the components and the balance is one hundred percent. The medicament has special effects on early and middle high fever, fulminant epidemic diseases from 2006 to 2009, mixed epidemic swine fever blue-eared disease of virus, pathogenic bacteria and worm, pseudorabies, blood worm, toxoplasmosis, lung plague, erysipelas, eircovims, streptococcus, haemophilus diseases, pneumonia, bronchitis and abdominal respiration and can relieve nose and mouth foaming in two hours.

The invention discloses a compound sulfamonomethoxine / compound sulfamonomethoxine sodium injection which is prepared from main components and auxilary components, wherein the main components comprise 5-20 parts by weight of sulfamonomethoxine / sulfamonomethoxine sodium, 1-4 parts by weight of diclofenac sodium and 1-4 parts by weight of trimethoprim and the auxilary components comprise 0.2-0.4 part by weight of antioxidant, 40-70 parts by weight of organic solvent, 0.2-1 part by weight of regulating reagent and 10-20 parts by weight of water for injection. The injection prepared by the invention can provide effective treatment on secondary infection and mixed infection of streptococcicosis, toxoplasmosis, eperythrozoonosis, colibacillosis, asthma and other diseases, has obvious effect if applied for a long term, strong effect enhanced by several times or dozens of times, hardly generates drug resistance and has the advantages of less consumption, less application times, little irritation and quick treatment effect, can treat both symptoms and root causes, save production cost, improve product additional value and reduce toxic or side effects caused by mismatching of medicaments during treatment.

The invention discloses a PCR detection reagent box of animal toxoplasmosis; the box contains DNA lysate, red blood cell lysate, white blood cell lysate, PCR reaction liquid and toxoplasmosis gene DNA positive control liquid; the 529bp repeated DNA segment of toxoplasmin is taken as genetic mark and special primer is taken to optimize the PCR reaction conditions such as the magnesium ion consistency, the anneal temperature and the regulation of the cycle number. The invention can detect the toxoplasmosis infection of pig, dog and cat in a fast special sensible way; the operation is convenient and the sensibility is high; the invention can be used for diagnosing the toxoplasmosis of pig, dog and cat and detecting and testing the drug effect appraisal of the selection of the toxoplasmosis medicines.

Traditional Chinese medicine feed additive for controlling swine toxoplasmosis is characterized by being made of material medicines including, by weight, 10 parts of herba schizonepetae, 12 parts of dried orange peel, 15 parts of apricot kernel, 15 parts of cortex phellodendri, 10 parts of coptis root, 35 parts of lightyellow sophora root, 2 parts of licorice root, 10 parts of Chinese angelica, and 15 parts of monkhood branched root. A preparation method includes mixing the material medicines before pulverizing, or respectively pulverizing the medicines before mixing. The traditional Chinese medicine feed additive can be mixed into pig feed for feeding according to the proportion of 0.5-0.7%. The selected medicinal materials for the traditional Chinese medicine feed additive have the effects of clearing heat and toxicity, dispelling wind-evil, killing parasites, and strengthening the body resistance to eliminate pathogenic factors. The traditional Chinese medicine feed additive has fine preventive and curative actions on swine toxoplasmosis.

Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii (T. gondii) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and / or imidazo[1,5-a]pyrazine inhibitors, of the formula,wherein the variables X, Y, Z, L, R1, and R3 are defined herein.

The invention discloses a compound sodium sulfadimidine injection liquid for a pig and a preparation method thereof, aiming at providing a compound kanamycin sulfate injection liquid which has fast effect for treating toxoplasmosis of the pig, addresses both the symptoms and root causes, reduces the time and dosage of used drug and has convenient drug usage, and a preparation method with simple technique and easy implementation. Each 100L injection liquid comprises: 5 to 20 sodium sulfadimidine, 1 to 10kg of lincomycin hydrochloride, 5 to 20kg of doxofylline, 1 to 4kg of trimethoprim, 0.2kg of sodium bisulfite, 0.01kg of EDTA-2Na, 40kg of propylene glycol, 10kg of 95% alcohol and the balance of water for injection. The injection liquid has fast effect for toxoplasmosis of the pig, addresses both the symptoms and root causes, can effectively treat and prevent secondary infection of bacterium, reduces drug resistance of pathogenic microorganism and leads the pig to accelerate restoring. Simultaneously, the compound sodium sulfadimidine injection liquid is an injection liquid and has convenient use.

The invention relates to a medicinal composition and injecta for curing avian toxoplasmosis, and a preparation method thereof. The medicinal composition comprises the following components in percentage by weight: 18 to 36 percent of sulfamonomethoxine, 16 to 65 percent of sulfamethoxazole, 7 to 18 percent of trimethoprim, 4 to 14 percent of pyrimethamine and 6 to 16 percent of nonsteroidal anti-inflammatory medicament. The injecta comprises the following components in percentage by weight: 5 to 10 percent of sulfamonomethoxine, 4 to 20 percent of sulfamethoxazole, 2 to 5 percent of trimethoprim, 1 to 3 percent of pyrimethamine, 1.5 to 4 percent of nonsteroidal anti-inflammatory medicament, 5 to 10 percent of polyethyleneglycol-400, 10 to 30 percent of propylene glycol, 30 to 60 percent of alpha-pyrrolidone, 0.1 to 0.2 percent of antioxidant, 0.01 to 0.02 percent of metal complexing agent and the balance of water for injection. Sulfamonomethoxine, sulfamethoxazole, trimethoprim and pyrimethamine are jointly applied and a long-acting preparation is prepared by adopting composite solvent, so that the medicinal composition and the injecta can prevent the secondary infection of other pathogen at the same time of destroying and expelling toxoplasma so as to relieve different symptoms and complicating diseases caused by the toxoplasma.

Uracil auxotroph mutants of apicomplexans are provided which lack a functional carbamoyl phosphate synthase II (CPSII) enzyme. Also provided are T. gondii autoxtroph mutants which express exogenous antigens, and methods of protecting an animal against a T. gondii and non-T. gondii disease.

The invention discloses a compound sulphamethoxazole injection and a preparation method thereof. The injection is prepared from 5-20 % of the main drug sulphamethoxazole, 2-10 % of flunixin meglumine, 1-4 % of trimethoprim, 0.2-0.4 % of an accessory anti-oxidant, 40-70 % of an organic solvent, 0.5-2 % of an adjusting reagent and the balance being water for injection. The injection prepared by the invention can provide effective treatment for secondary infections and mixed infections of streptococcus diseases, toxoplasmosis, eperythrozoonosis, E. coli diseases, asthma and other diseases, is obvious in long-term effects, with a drug effect being enhanced by several times to dozens of times, small in application amount, few in drug using times, little in irritation and fast in performance of drug effects, saves production cost, increases added value of products, and reduces toxic and side effects due to drug mismatch during treatment.

The present invention belongs to the field of biotechnology, and relates to a surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment, encoded gene and use thereof. According to the invention, the surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment is filtered from a base through establishing a Toxoplasma gondii human immunoglobulin, ELISA, diluting the prothrombin time, sequencing analysis, etc. Through expression purifying and authenticating, the human antigen Fab fragment is authenticated to specifically identify the tachyzoite-bradyzoite recombination SAG1 of Toxoplasma gondii and have higher affinity with the tachyzoite-bradyzoite recombination SAG1 of Toxoplasma gondii, for being identified with the specificity of Toxoplasma gondii tachyzoite-bradyzoite. The human antigen Fab fragment of the invention does not contain Fc segment and does not activate the alexin or cause the histopathological damages of human immune response, etc. when the function of restricting the invasion of Toxoplasma gondii to the host cell is exerted. The surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment is safe and reliable when applied for the human body. The antigen medicine for treating toxoplasmosis or the antigen targeted medicine can be prepared.

The invention relates to a drug combined health-care mosquito incense for livestock. The mosquito incense provided by the invention is prepared by the following steps of: weighing pharmaceutical materials of herba schizonepetae, radix sileris, platycodon root, mint, liquorice, folium artemisiae argyi, honeysuckle and rhizoma coptidis according to a reasonable proportion, removing impurities, washing and drying in the sun, mixing the pharmaceutical materials with high-quality carbon, corncob and a synergist (such as piperonyl butoxide, asarinin, SVI and propylisome) according to a reasonable proportion, grinding into fine powders of 100-200 meshes, mixing the fine powders, fully and uniformly stirring, moulding, spraying an appropriate proportion of cyfluthrin, drying, sealing with a plastic film, packaging, warehousing, and selling or storing for standby. The mosquito incense is ignited for fumigating an animal house so as to expel flies and mosquitoes, Simuliidae and Culicoides in summer, inhibit bacteria, change smell in the animal house and purify the environment. Therefore, dissemination medium is cut out, and simultaneously mycoplasma suis, toxoplasmosis, leucocytozoosis and the like are also prevented. The mosquito incense provide by the invention has advantages of wide drug effect range, big smoke and long combustion time (10-12 hours), is nontoxic, has no side effect, and is convenient and fast to use.

The invention provides polypeptide fragments derived from TgAMA-1, nucleic acids that encode the polypeptide fragments, and TgAMA-binding polypeptides such as antibodies. Methods for using the polypeptide and nucleic acid molecules to produce vaccines are also provided. In addition the invention provides methods involving use of the polypeptides, nucleic acids, and binding polypeptides, such as antibodies, for the prevention and treatment of Toxoplasmosis.

The invention relates to a feed additive for preventing and treating swine toxoplasmosis. The feed additive comprises the following components: honeysuckle, radix sophorae flavescentis, radix polygonati officinalis, cowherb seed, sage, poria cocos, mirabilite, crude dragon bone, polygala tenuifolia, coptis chinensis, radix bupleuri, mangnolia officinalis, patrinavillosajuss, sculellaria barbata, radix angelicae pubescentis, sanguisorba officinalis and scorpio. The feed additive for preventing and treating swine toxoplasmosis provided by the invention adopts a traditional Chinese medicine preparation; the swine toxoplasmosis can be effectively prevented and treated; the disease resistance of the pig is improved; the morbidity of the pig in the growth process is reduced; the growth speed of the pig is improved; the feed additive is prepared from traditional Chinese medicine components, and is free of residual toxicity; and the pork quality can be improved.

The invention discloses a DNA vaccine for preventing toxoplasmosis of humans or animals. An ROP19 gene is amplified through PCR, the amplified ROP19 gene is inserted into a eukaryotic expression vector pEGFP-C1 to build recombinant plasmid pEGFP-C1-ROP19 (pROP19), the recombinant plasmid containing a target gene is extracted, and the toxoplasma gondii ROP19DNA vaccine is obtained. According to the DNA vaccine for preventing the toxoplasmosis of the humans or the animals, active immunization is conducted on BALB / c mice through the DNA vaccine, the immunogenicity of the vaccine is evaluated by determining cells and humoral immunity indexes of immunized mice, and the immunoprotectivity of the vaccine is estimated by counting the number of cysts in brains of the mice and the survival rate of the mice after attack experiments of toxoplasma gondii are conducted. By means of the DNA vaccine for preventing the toxoplasmosis of the humans or the animals, humoral immunity and cellular immune responses can be effectively enhanced, the formation rate of the brain cysts of the immune mice attacked by a toxoplasma gondii PRU strain (II type) is effectively decreased, and the survival time of the mice attacked by a toxoplasma gondii RH stain (I type) is prolonged.

The invention provides a Chinese medicinal composition treating toxoplasmosis. Being an orally taken medicine, the Chinese medicinal composition contains the following four herbal medicines: astragalus, artemisia apiacea, licorice, and betel nuts, and can be used for treating toxoplasmosis in human and animals. The Chinese medicinal composition can be decocted in water and then used directly, and also can be made into an oral liquid, a tablet and other orally taken medicines for clinical use. Drugs prepared from the Chinese medicinal composition involved in the invention have good effects and low prices.

The invention discloses a toxoplasma gondii fluorogenic quantitative PCR specific primer, a kit and a detecting method of the toxoplasma gondii fluorogenic quantitative PCR specific primer. The kit comprises the toxoplasma gondii fluorogenic quantitative PCR specific primer, a DNA extracting solution, a fluorogenic quantitative PCR reacting solution, a quality-controlling reacting solution, Spin Columns CB3 and Collection Tubes 2ml. According to the kit, GRA7 gene is utilized as a genetic marker, and the specific primer is used for optimizing PCR reacting system conditions like reagent concentration and temperature. Thus, the kit can quickly, specifically and flexibly detect whether animals are infected by toxoplasmosis, is convenient to operate and can be applied to diagnosis of various kinds of animal toxoplasmosis.

The invention relates to an indirect ELISA kit for cat toxoplasma gondii serum antibody and a preparation method thereof. The toxoplasma gondii in serum is detected by adopting toxoplasma gondii surface protein SAG3 as a coating antigen; an indirect ELISA method is established by adopting HRP marked goat anti-cat IgG as a detection antibody, which has relatively strong specificity, sensitivity and repeatability; according to the invention, except for the fact that the washing liquid is powder, the main reagents can be directly applied after being dissolved in water; for the kit, the laboratory detection washing liquid is used as a basic solution, and the rest all exists in a form of liquid working solution, thus the kit is convenient to use; and the invention provides a convenient and reliable immunological diagnosis method for large sample detection and epidemiological survey and provides a basis for the diagnosis of cat toxoplasmosis.

The invention relates to a Toxoplasma gondii rapid detection kit and a preparation method thereof. The kit is based on the molecular biology and the nucleoside triphosphate hydrolase (NTPase) gene with high conservation of Toxoplasma gondii to adopt the loop-mediated isothermal amplification (LAMP) method to perform the rapid detection of Toxoplasma gondii. The kit contains LAMP reaction solution, primer, Bst DNA polymerase, color reagent, standard positive template and dd H2O. The kit of the invention is characterized by high sensitivity and specificity, rapid reaction, simple operation and the like, does not require special instrument and equipment and solves the defects of the prior art such as long detection time of toxoplasmosis, large workload and complicated operation. The kit of the invention can be used to detect whether a clinical sample contains Toxoplasma gondii and used in the early diagnosis and the molecular epidemiological study of toxoplasmosis.

The invention discloses an indirect ELISA diagnostic kit for toxoplasmosis. A detection antigen used by the indirect ELISA diagnostic kit is recombinant protein rTgPP1 obtained after prokaryotic expression of a Toxoplasma gondii TgPP1 gene with a nucleotide sequence as shown in SEQ ID No. 1. The coating antigen in the kit is the prokaryotically expressed protein rTgPP1 which exists in a soluble manner under low-temperature induction and has a His tag in its N terminal, which is beneficial for large-scale purification of the protein rTgPP1 and emancipates antigen source from constraints. According to the invention, a recombinant antigen replaces a natural antigen and is applied as the coating antigen to ELIDA detection and preparation of the ELISA diagnostic kit, so the stability of antigens of different batches can be substantially improved, good specificity and repeatability are obtained, and a rapid and effective detection method is provided for epidemiological investigation and disease diagnosis.

The present invention can provide a novel medicament that is safe, cheap and effective for prophylaxis or therapy of apicomplexan infections, such as malaria and toxoplasmosis by applying a plant growth regulator selected from the group consisting of gibberellin inhibitors, cytokinins and ethylene inhibitors to the prophylactic or therapeutic treatment of such apicomplexan infections.

The invention discloses a traditional Chinese medicine composition for treating swine toxoplasmosis as well as a preparation and an application thereof. The traditional Chinese medicine composition is liquid medicine prepared by the following steps of: adding distilled water to mix with urena lobata, inula cappa, Cinchona succirubra and liquorice and decoct for 1-3 times, combining decoction, concentrating the decoction to be in a thick state, adding ethyl alcohol with the concentration of 90-95% to regulate the ethyl alcohol concentration to be 60-70%, precipitating, filtering and concentrating filter liquor; adding ethyl alcohol with the concentration of 90-95% into the concentrated filter liquor to regulate the ethyl alcohol concentration to be 75-80%, precipitating, filtering, and concentrating filter liquor; and adding distilled water into the concentrated filter liquor, refrigerating, precipitating, filtering, and concentrating to obtain the liquid medicine. The traditional Chinese medicine composition has a recovery rate to the swine toxoplasmosis being more than 90% and less side effects, and is safe and convenient to use, low in use amount and quick to absorb.

The invention discloses a toxoplasma gondii dense granular protein GRA1. A nucleotide sequence for encoding the protein is shown as SEQ ID NO:1. The invention further discloses an application of the dense granular protein GRA1 to the preparation of an enzyme-linked immunoassay detecting kit for treating toxoplasmosis and an enzyme-linked immunoassay method for detecting a sheep toxoplasma gondii IgG antibody. The method has the advantages such as high sensitivity, strong specificity, good accuracy as well as high speed, simplicity and convenience when being used for detecting the toxoplasmosis.

The present invention relates to a method for preparing a cyclic peptide with antiparasite activity and anticancer activity. The invention also relates to this peptide as an antiparasite agent, for example in the treatment of toxoplasmosis and as an anticancer agent. The invention also relates to the use of this cyclic peptide for treating organs ex vivo before transplantation.

The invention relates to the technical field of preparation of disease detection reagents and discloses a specific detection primer for swine toxoplasmosis and a detection kit. A dense granular protein 14 (GRA14) gene is taken as a target gene for diagnosis of the swine toxoplasmosis, specific detection primer GRAF-3 and GRAR-3 for toxoplasmosis are designed and screened out, and the sequence of each of the GRAF-3 and GRAR-3 is as shown as in SEQ ID No:1 and SEQ ID No.2. The toxoplasmosis is detected through the primer which is highly specific and highly flexibly, the result of a PCR (polymerase chain reaction) is easy to judge, epidemiological investigation for the toxoplasmosis and detection and clinical diagnosis of invisible infection can be realized by the aid the detection kit for the toxoplasmosis, prepared from the primer, and a foundation is laid for further research on diagnostic and preventive techniques and the like of the toxoplasmosis.